ENVERIC BIOSCIENCES INC (ENVB) Stock Overview
USA - NASDAQ:ENVB - US29405E4061 - Common Stock
ENVB Key Statistics, Chart & Performance
The current stock price of ENVB is 6.9949 USD. In the past month the price increased by 1013.54%. In the past year, price decreased by -3.46%.
ENVB Latest News, Press Relases and Analysis
ENVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.79 | 776.28B | ||
| JNJ | JOHNSON & JOHNSON | 17.86 | 446.39B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.59 | 255.89B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.51 | 236.43B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.52 | 233.64B | ||
| MRK | MERCK & CO. INC. | 11.3 | 217.38B | ||
| PFE | PFIZER INC | 7.22 | 139.07B | ||
| SNY | SANOFI-ADR | 11.65 | 125.51B | ||
| GSK | GSK PLC-SPON ADR | 10.34 | 92.74B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 86.74B | ||
| ZTS | ZOETIS INC | 23.42 | 64.55B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.57 | 43.84B |
Related stock screener links
About ENVB
Company Profile
Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The firm is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Company Info
ENVERIC BIOSCIENCES INC
245 First Street Riverview Ii 18Th Floor
Cambridge MASSACHUSETTS 34103 US
CEO: David Johnson
Employees: 5
Phone: 12393021707
ENVERIC BIOSCIENCES INC / ENVB FAQ
What does ENVB do?
Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The firm is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
What is the stock price of ENVERIC BIOSCIENCES INC today?
The current stock price of ENVB is 6.9949 USD. The price decreased by -1.76% in the last trading session.
What is the dividend status of ENVERIC BIOSCIENCES INC?
ENVB does not pay a dividend.
What is the ChartMill rating of ENVERIC BIOSCIENCES INC stock?
ENVB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of ENVERIC BIOSCIENCES INC (ENVB) based on its PE ratio?
ENVERIC BIOSCIENCES INC (ENVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.3).
What is the market capitalization of ENVB stock?
ENVERIC BIOSCIENCES INC (ENVB) has a market capitalization of 22.73M USD. This makes ENVB a Nano Cap stock.
ENVB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ENVB. When comparing the yearly performance of all stocks, ENVB is one of the better performing stocks in the market, outperforming 98.81% of all stocks.
ENVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENVB. The financial health of ENVB is average, but there are quite some concerns on its profitability.
ENVB Financial Highlights
Over the last trailing twelve months ENVB reported a non-GAAP Earnings per Share(EPS) of -21.3. The EPS increased by 80.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -280.2% | ||
| ROE | -455.09% | ||
| Debt/Equity | 0 |
ENVB Forecast & Estimates
7 analysts have analysed ENVB and the average price target is 10.2 USD. This implies a price increase of 45.82% is expected in the next year compared to the current price of 6.9949.